Safety of pasteurised <i>Akkermansia ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Permalink :
Title :
Safety of pasteurised <i>Akkermansia muciniphila</i> as a novel food pursuant to Regulation (EU) 2015/2283.
Author(s) :
Turck, Dominique [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Bohn, T. [Auteur]
European Food Safety Authority [EFSA]
Castenmiller, J. [Auteur]
De Henauw, S. [Auteur]
Hirsch-Ernst, K. I. [Auteur]
Maciuk, A. [Auteur]
Mangelsdorf, I. [Auteur]
Mcardle, H. J. [Auteur]
Naska, A. [Auteur]
Pelaez, C. [Auteur]
Pentieva, K. [Auteur]
Siani, A. [Auteur]
Thies, F. [Auteur]
Tsabouri, S. [Auteur]
Vinceti, M. [Auteur]
Cubadda, F. [Auteur]
Frenzel, T. [Auteur]
Heinonen, M. [Auteur]
Marchelli, R. [Auteur]
Neuhäuser-Berthold, M. [Auteur]
Poulsen, M. [Auteur]
Prieto Maradona, M. [Auteur]
Schlatter, J. R. [Auteur]
Van Loveren, H. [Auteur]
Ackerl, R. [Auteur]
Knutsen, H. K. [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Bohn, T. [Auteur]
European Food Safety Authority [EFSA]
Castenmiller, J. [Auteur]
De Henauw, S. [Auteur]
Hirsch-Ernst, K. I. [Auteur]
Maciuk, A. [Auteur]
Mangelsdorf, I. [Auteur]
Mcardle, H. J. [Auteur]
Naska, A. [Auteur]
Pelaez, C. [Auteur]
Pentieva, K. [Auteur]
Siani, A. [Auteur]
Thies, F. [Auteur]
Tsabouri, S. [Auteur]
Vinceti, M. [Auteur]
Cubadda, F. [Auteur]
Frenzel, T. [Auteur]
Heinonen, M. [Auteur]
Marchelli, R. [Auteur]
Neuhäuser-Berthold, M. [Auteur]
Poulsen, M. [Auteur]
Prieto Maradona, M. [Auteur]
Schlatter, J. R. [Auteur]
Van Loveren, H. [Auteur]
Ackerl, R. [Auteur]
Knutsen, H. K. [Auteur]
Journal title :
EFSA Journal
Abbreviated title :
EFSA J
Volume number :
19
Pages :
e06780
Publication date :
2021-09-13
ISSN :
1831-4732
English keyword(s) :
Akkermansia muciniphila
novel food
food supplement
gut microbiota
safety
novel food
food supplement
gut microbiota
safety
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods andFood Allergens (NDA) was asked to deliver an opinion on pasteurisedAkkermansia muciniphilaas anovel food (NF) pursuant to ...
Show more >Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods andFood Allergens (NDA) was asked to deliver an opinion on pasteurisedAkkermansia muciniphilaas anovel food (NF) pursuant to Regulation (EU) 2015/2283.A. muciniphilais a well-characterised non-toxin producing, avirulent microorganism that has been reported as part of normal gut microbiota. TheNF, pasteurisedA. muciniphila, is proposed by the applicant to be used as a food supplement at max.591010cells/day by adults excluding pregnant and lactating women, and in foods for special medicalpurposes. The Panel considers that the production process of the NF is sufficiently described and thatthe information provided on the composition of the NF is sufficient for its characterisation. Taking intoaccount the composition of the NF and the proposed conditions of use, the consumption of the NF isnot nutritionally disadvantageous. Based on literature data, and by applying an uncertainty factor of200 to the no observed adverse effect level (NOAEL) of a 90-day repeated dose oral toxicity study inrats, the Panel concludes that the consumption of 3.491010cells/day is safe for the target populationunder the provision that the number of viable cells in the NF is<10 colony forming units (CFU)/g (i.e.limit of detection)Show less >
Show more >Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods andFood Allergens (NDA) was asked to deliver an opinion on pasteurisedAkkermansia muciniphilaas anovel food (NF) pursuant to Regulation (EU) 2015/2283.A. muciniphilais a well-characterised non-toxin producing, avirulent microorganism that has been reported as part of normal gut microbiota. TheNF, pasteurisedA. muciniphila, is proposed by the applicant to be used as a food supplement at max.591010cells/day by adults excluding pregnant and lactating women, and in foods for special medicalpurposes. The Panel considers that the production process of the NF is sufficiently described and thatthe information provided on the composition of the NF is sufficient for its characterisation. Taking intoaccount the composition of the NF and the proposed conditions of use, the consumption of the NF isnot nutritionally disadvantageous. Based on literature data, and by applying an uncertainty factor of200 to the no observed adverse effect level (NOAEL) of a 90-day repeated dose oral toxicity study inrats, the Panel concludes that the consumption of 3.491010cells/day is safe for the target populationunder the provision that the number of viable cells in the NF is<10 colony forming units (CFU)/g (i.e.limit of detection)Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Submission date :
2024-01-12T06:05:07Z
2024-03-01T13:32:17Z
2024-03-01T13:32:17Z
Files
- EFSA Journal - 2021 - - Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation EU 2015.pdf
- Version éditeur
- Open access
- Access the document
Except where otherwise noted, this item's license is described as Attribution-NoDerivs 3.0 United States